We’re partnering with Enterin to develop a potential new treatment for Parkinson’s dementia
We’re investing £2m in Enterin’s phase 2 clinical trial of its drug ENT-01, a potential treatment for Parkinson’s dementia.
In January 2022, Enterin, a biotech company based in the United States, announced promising results from a trial in 150 people with Parkinson’s.
In this study, some of the trial participants had Parkinson’s associated dementia and showed improvement in cognitive function (mental abilities, such as remembering or problem solving) during the 10-week treatment period.
They continued to see improvements in the 6 weeks following the treatment, showing that this treatment may have a significant impact on the progression of the condition.
Participants also saw an improvement in a range of non-motor symptoms (symptoms which do not affect movement), including bowel function, dementia, psychosis (hallucinations and delusions) and sleep problems.
Enterin’s new phase 2b trial, in collaboration with the Parkinson’s Virtual Biotech, will try to replicate the improvements in cognition seen in previous trials.
Arthur Roach, Director of Research at Parkinson’s UK, said:
"Through the Parkinson’s Virtual Biotech, we’re very excited to be working with Enterin as they look to develop a potential new treatment for Parkinson’s dementia.
"Parkinson’s is the fastest growing neurological condition in the world and currently there is no cure. We can only treat and manage the symptoms of which there are more than 40.
"While Parkinson’s is more commonly associated with motor symptoms like tremor, our community has asked us to make new and better treatments for Parkinson’s dementia a priority. We are encouraged by the clinical results that Enterin’s work has produced to date and look forward to the upcoming clinical trial which will have sites in the UK as well as in America."
David McCullough, CEO of Enterin, said:
"Enterin is very grateful to partner with such a prestigious and well-respected organisation. We have worked closely with Parkinson’s UK and their clinical advisors to design a clinical study to evaluate ENT-01 in PD dementia. It is our hope that we can offer a new therapeutic option for these patients."
Read more
Your donation could change lives. In years, not decades. Join the fight to bring the next breakthrough closer and transform the lives of everyone living with Parkinson's, and the people who love and care for them.
The Parkinson’s Virtual Biotech is a groundbreaking global movement to deliver life-changing new treatments in years not decades.